2017
Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status
Gowda C, Newcomb CW, Liu Q, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Roy JA, Marks AR, Schneider JL, Kostman JR, Tate JP, Lim JK, Justice AC, Goetz MB, Corley DA, Re V. Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status. Open Forum Infectious Diseases 2017, 4: ofx012. PMID: 28470014, PMCID: PMC5407218, DOI: 10.1093/ofid/ofx012.Peer-Reviewed Original ResearchSevere acute liver injuryAcute liver injuryViral hepatitis statusAntiretroviral therapyHepatitis statusAminotransferase elevationHazard ratioLiver aminotransferasesLiver injuryHigh riskHIV/viral hepatitisKaiser Permanente Northern CaliforniaVeterans Aging Cohort StudyNonnucleoside reverse transcriptase inhibitorAbacavir/lamivudineProtease inhibitor useTenofovir/emtricitabineAging Cohort StudyHuman immunodeficiency virusRisk of hepatotoxicityConfidence intervalsReverse transcriptase inhibitorART initiationCoinfected PatientsART regimens
2010
Virologic and immunologic response to HAART, by age and regimen class
Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, Gill MJ, Lau B, Napravnik S, Tedaldi E, Klein MB, Gebo KA. Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010, 24: 2469-2479. PMID: 20829678, PMCID: PMC3136814, DOI: 10.1097/qad.0b013e32833e6d14.Peer-Reviewed Original ResearchConceptsCD4 cell countImmunologic responseNorth American AIDS Cohort CollaborationCell countMean CD4 cell countProtease inhibitor-based regimenNonnucleoside reverse transcriptase inhibitorAntiretroviral-naive adultsInhibitor-based regimenInitial antiretroviral regimenProspective cohort studyConfidence intervalsReverse transcriptase inhibitorImpact of ageInverse probability weightsCohort CollaborationInitial regimenAntiretroviral regimenVirologic responseCohort studyViral loadEligible participantsOdds ratioTranscriptase inhibitorRegimen